Solutions

Pharma Companies
Private Hospitals
High-end health & fitness clubs

IppocraTech, is an Italian startup with an unfair advantage:

its AI technology is able to measure

THE 5 VITAL SIGNS defined by WHO to assess a person’s health status_larger_font
5-removebg

Other Advantages

  • Algorithms integrable with third-party devices
  • Software API for third-party integration
  • Telemedicine platform integrated in the technology
  • Very competitive price vs other medical devices

IppocraTech, is an Italian startup with an unfair advantage:

its AI technology is able to measure

THE 5 VITAL SIGNS defined by WHO to assess a person’s health status_larger_font
5-removebg

Other Advantages

  • Algorithms integrable with third-party devices
  • Software API for third-party integration
  • Telemedicine platform integrated in the technology
  • Very competitive price vs other medical devices

WHY 5 VITAL SIGNS?

respirology_white

Respiration Rate

heart_cardiogram_white

Heart Rate

oxygen_tank_white

Blood Saturation

blood_pressure_2_white

Blood Pressure

thermometer_white

Temperature

The World Health Organization

determined that these five parameters together with the state of consciousness and the color of the skin are the main indicators to understand an individual’s state of health. To have a correct evaluation of these vital signs, they must not be tested under stress or during physical activity.

who-logo-black-and-white

IppocraTech

has developed a proprietary technology that can simultaneously measure all five vital signs, increasing its precision level compared to traditional devices and allowing the medical doctor to observe health data trends and correlations simultaneously, bringing additional insights into the possible diagnosis.

Clinical cases where

IppocraTech technology can make the difference

Recording simultaneously the five vital signs allow the medical doctor an early evaluation of diseases thanks to
the simultaneous change of the vital signs relative to each other
blood_pressure_blue350x350
Arterial Hypertension
  • Level of diffusion

    30-45% of the adult population (half of these do not know they are affected because they do not show symptoms)

  • Consequences

    stroke, heart attack,
    heart failure, kidney failure

  • Blood pressure

    using IppocraTech technology, a medical doctor can quickly check the patient's blood pressure trend and immediately detect if it is dangerously increasing

defibrilator_blue350x350
Atrial Fibrillation
  • Level of diffusion

    30% of the population over 65 years old

  • Using IppocraTech technology

    a medical doctor can diagnose a atrial fibrillation looking at ECG trace

lungs_blue350x350
Pulmonary Embolism
  • Level of diffusion

    acute pulmonary artery occlusion is fatal in 70% of cases and can affect even young subjects

  • Using IppocraTech technology

    a medical doctor can detect a possible pulmonary embolism in time thanks to the simultaneous reporting of the heart rate increase, the blood pressure fall, and the saturation fall

observation_blue350x350
Chronic Obstructive Pulmonary Disease
  • Level of diffusion

    550 million people. It is one of the widespread chronic respiratory disease, with a significant burden on the quality of life

  • Using IppocraTech technology

    a medical doctor can detect a possible acute exacerbation of COPD in time thanks to the simultaneous reporting of the respiratory rate increase, the saturation fall, and the heart rate increase

stethoscope_blue350x350
Cancer
  • Using IppocraTech technology

    a medical doctor can remotely monitor chemotherapy's effects on cancer patients (e.g., cardio-toxicity development)

Sources: 2018 ESC/ESH Guidelines for the management of arterial hypertension; 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS); The global impact of Aspergillus infection on COPD, Emily E. Hammond, Charles S. McDonald, Jørgen Vestbo, and David W. Denning, BMP Pulmonary Medicine, 2020.

Awards

Marzotto Venture Accelerator Covid-19 Challenge (2020)

ROP ERDF Emilia-Romagna Solutions to contrast the spread of Covid-19 (2020)

ANT 'Franco Pannuti's Award' (2021)

Daiichi Sankyo Cardiotech Accelerator (2022)

"Rotary International 2072 District" Startup Award (2022)

Roche - for indipendent research (2022)

GVM – HealthBio Accelerator (2022)

Medtronic – Heart Failure Hackathon (2022)

smart&start_invitalia_con_drappo_alt_2

Clinical publications

Mattioli AVBallerini Puviani MMalagoli A
"Quarantine and Isolation during COVID-19 outbreak: A case of online diagnosis of supraventricular arrhythmia through telemedicine."
J Arrhythmia2020361114– 1116https://doi.org/10.1002/joa3.12431
             https://onlinelibrary.wiley.com/doi/10.1002/joa3.12431
Mattioli AV, Cossarizza A, Boriani G
"COVID-19 pandemic: usefulness of telemedicine in management of arrhythmias in elderly people."
J Geriatr Cardiol. 2020;17(9):593-596. doi:10.11909/j.issn.1671-5411.2020.09.010
            https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568046/
Maffei F, Nasi M, Vittori L, Bragonzoni L, Toselli S, Tripi F, Mattioli A, Maietta-Latessa P
"Adherence to an adapted physical activity program in sedentary adults."
Journal of Human Sport and Exercise, 17(1), 39-50. doi:https://doi.org/10.14198/jhse.2022.171.05
                https://www.jhse.ua.es/article/view/2022-v17-n1-adapted-physical-activity-program-sedentary-adults
Coppi F, Pinti M, Selleri V, Zanini G, D'Alisera R, Latessa PM, Tripi F, Savino G, Cossarizza A, Nasi M, Mattioli AV
"Cardiovascular Effects of Whole-Body Cryotherapy in Non-professional Athletes."
Frontiers in Cardiovascular Medicine. 2022 Jun 10;9:905790.
doi: 10.3389/fcvm.2022.905790.
                 https://www.frontiersin.org/articles/10.3389/fcvm.2022.905790/full

Clinical trials

Università degli studi di Modena e Reggio Emilia
Istituto Nazionale per le Ricerche Cardiovascolari
Fondazione ANT Italia Onlus